Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An adjuvant strategy enabled by modulation of the physical properties of fungal ligands expands viral glycoprotein immunogenicity

ABSTRACT: An adjuvant strategy enabled by modulation of the physical properties of fungal ligands expands viral glycoprotein immunogenicity

PROVIDER: PRJNA796058 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17542208_1.fastq.gz	Fastqsanger.gz
	SRR17542208_2.fastq.gz	Fastqsanger.gz
	SRR17542209_1.fastq.gz	Fastqsanger.gz
	SRR17542209_2.fastq.gz	Fastqsanger.gz
	SRR17542210_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 76

Similar Datasets

An adjuvant strategy enabled by modulation of the physical properties of fungal ligands expands viral glycoprotein immunogenicity

Project description:Activation of the innate immune system via pattern recognition receptors (PRRs) is key to generate lasting adaptive immunity. PRRs detect unique chemical patterns associated with invading microorganism, but if and how the physical properties of PRR ligands influence development of the immune response remains unknown. Through the study of fungal mannans we show that the physical form of PRR ligands dictates the immune response. Soluble mannans are immunosilent in the periphery but elicit a potent pro-inflammatory response in the draining lymph node (dLN). By modulating the physical form of mannans, we developed a formulation that targets both the periphery and dLN. When combined with viral glycoprotein antigens, this mannan formulation broadens epitope recognition, elicits potent antigen-specific neutralizing antibodies, and confers protection against viral infections of the lung. Thus, the physical properties of microbial ligands determine the outcome of the immune response and can be harnessed for vaccine development.

2022-01-13 | GSE193419 | GEO

An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.

Project description:Activation of the innate immune system via pattern recognition receptors (PRRs) is key to generate lasting adaptive immunity. PRRs detect unique chemical patterns associated with invading microorganisms, but whether and how the physical properties of PRR ligands influence the development of the immune response remains unknown. Through the study of fungal mannans, we show that the physical form of PRR ligands dictates the immune response. Soluble mannans are immunosilent in the periphery but elicit a potent pro-inflammatory response in the draining lymph node (dLN). By modulating the physical form of mannans, we developed a formulation that targets both the periphery and the dLN. When combined with viral glycoprotein antigens, this mannan formulation broadens epitope recognition, elicits potent antigen-specific neutralizing antibodies, and confers protection against viral infections of the lung. Thus, the physical properties of microbial ligands determine the outcome of the immune response and can be harnessed for vaccine development.

| S-EPMC8857056 | biostudies-literature

Mannose Receptor glycoprotein ligands in A549 cells

Project description:The macrophage mannose receptor (CD206, MR) is an endocytic lectin receptor which plays an important role in homeostasis and innate immunity. The MR contains C-type lectin domains (CTLD) whose specificity for endogenous glycans and glycoprotein ligands have not been well studied. To gain more insights into the recognition by the MR, we used the murine MR CTLD 4-7 coupled to the Fc-part of IgG (MR-Fc) to investigate its glycan and glycoprotein recognition. As lung cancer tissue and the lung cancer cell line A549 showed intense MR-Fc binding, we further investigated the MR glycoprotein ligands in those cells by immunoprecipitation and glycoproteomic analysis. All enriched glycoproteins, of which 42 were identified, contained pauci- or oligomannose N-glycans, confirming the microarray results. Our study demonstrates that the MR CTLD4-7 is highly selective for pauci- and oligomannosidic N-glycans, structures that are often elevated in tumor cells, and suggest a potential role for the MR in tumor biology.

2022-06-21 | PXD022546 | Pride

TXNIP loss expands Myc transcriptome

Project description:TXNIP loss expands Myc transcriptome

| PRJNA923027 | ENA

3’ Uridylation Expands miRNA Target Repertoire

Project description:3’ Uridylation Expands miRNA Target Repertoire

| PRJNA497065 | ENA

Genomic-Enabled Medicine for Recurrent Glioblastoma

Project description:Genomic-Enabled Medicine for Recurrent Glioblastoma

| PRJNA408009 | ENA

Genomic-Enabled Medicine for Recurrent Glioblastoma

Project description:Genomic-Enabled Medicine for Recurrent Glioblastoma

| PRJNA408010 | ENA

TXNIP loss expands Myc transcriptome [RNA-seq]

Project description:TXNIP loss expands Myc transcriptome [RNA-seq]

| PRJNA859857 | ENA

Pressure-enabled Delivery in Radioembolization (TriNav Study)

Project description:The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System * Standard 2.4F microcatheter, not otherwise specified

| 2396082 | ecrin-mdr-crc

Immunogenicity and protective efficacy of Marburg virus glycoprotein and virus-like particle-forming mRNA-based vaccines.

Project description:Mounting evidence suggests the high immunogenicity of virus-like particle (VLPs) based vaccines. Although VLP vaccines can be effective, they have not been compared to an envelope glycoprotein (GP)-only vaccine for filoviruses. We conducted a detailed side-by-side comparison of the immunogenicity and protective efficacy of mRNA vaccines encoding for the Marburg virus (MARV) full length GP delivered alone or as a VLP. As expected, co-formulation of the MARV GP and matrix protein VP40 resulted in the formation of VLPs readily detected by electron microscopy after purification from cell supernatants. We vaccinated guinea pigs with a two-component mRNA vaccine encoding for GP and VP40 (from now on referred as VLP vaccine) or a monovalent mRNA vaccine encoding for GP alone. At high vaccine doses, the VLP group demonstrated reduced humoral response as compared to the GP-only group, but both mRNA vaccines fully protected guinea pigs against lethal MARV infection. However, at low doses, GP-only mRNA conferred a 100% protection, whereas the VLP exhibited only a partial protection. In mice the VLP mRNA vaccine was more efficient at inducing GP-specific CD8+ T cells co-expressing IFN-γ and TNF-α, whereas the GP-only mRNA vaccine better induced CD4+ T cells expressing IFN-γ, IL-2 and TNF-α. In addition, in guinea pigs, the VLP vaccine was associated with down-regulation of genes associated with various biological and metabolic processes, including the NF-κB signaling pathway, post-transcriptional silencing of small RNAs, and upregulation of genes involved in the mitochondrial respiratory chain complex. In contrast, the GP-only vaccine upregulated genes involved in interferon signaling. Overall, the VLP mRNA vaccine was less immunogenic and protective, whereas the GP-only mRNA vaccine conferred a robust protection by as little as one µg dose in guinea pigs.

2025-06-27 | GSE298124 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data